| (Mark One) | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF |   |
|------------|--------------------------------------------------|--------|
| x          | THE SECURITIES EXCHANGE ACT OF 1934              |   |

| Georgia                                                        | 22-2408354                           |
|----------------------------------------------------------------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
|                                                           |                                 |
| 3130 GATEWAY DRIVE, P.O. BOX 5625                              | 30091-5625                           |
| Norcross, Georgia                                              | (Zip Code)                           |
| (Address of principal executive offices)                       |                                 |

| Title of Each Class          | Name of Each Exchange on Which Registered |
|------------------------------|-------------------------------------------|
| COMMON STOCK, $.10 PAR VALUE | The Nasdaq Stock Market LLC               |
| COMMON STOCK PURCHASE RIGHTS |                                      |

----

| Large accelerated filer     | x | Accelerated filer  | o |
|-----------------------------|---|-------------------------|---|
| Non-accelerated filer  | o | Small reporting company | o |

----

| Name of Director       |   | Age | Position and Biographical information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| James F. Clouser  |   | 60  | James F. Clouser, a director of the Company since 2008, served from 1988 to 1999 as President, CEO and a board member of SteriGenics International, a global leader in medical device sterilization services, where he led the initial public offering of SteriGenics shares.  He has also served as President, COO or CFO of several public and private healthcare and technology companies, including Ion Beam Applications, S.A., Attain Inc. and Diasonics Inc.  Mr. Clouser holds an MBA in Finance from Wayne State University, Detroit, MI and a Masters of Accounting from Rochester Institute of Technology, Rochester, NY.  He is a member of the American Institute of Certified Public Accountants.  The Board believes that Mr. Clouser’s combination of financial, operational and leadership experience in the healthcare and medical technology industries enables him to make valuable contributions to the Board and to the Company, especially in the areas of financial and risk management, business development and strategic planning.                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Joshua H. Levine       |   | 52  | Mr. Levine serves as President and Chief Executive Officer and joined the Company in June 2011.  From 2004 to 2009, Mr. Levine was the President and Chief Executive Officer of Mentor Corporation, a New York Stock Exchange listed medical device manufacturer in the aesthetic medicine industry.  Mr. Levine was also a member of Mentor’s board of directors from 2004 to 2009.  Mr. Levine led the transformation of Mentor Corporation into a pure play aesthetic medicine company and a global leader in its market. Acquired by Johnson and Johnson in 2009, Mentor had more than 1,200 employees worldwide and approximately $375 million in annual revenue.   Mr. Levine served as the Worldwide President of Mentor Worldwide, LLC during Mentor’s integration into Johnson & Johnson in 2009 and 2010.  Mr. Levine’s tenure with Mentor spanned 14 years. He previously held various executive positions at Mentor, including Chief Operating Officer. Previously, Mr. Levine served with Kinetic Concepts, Inc., American Hospital Supply Corporation and Baxter International. Mr. Levine graduated from the University of Arizona.                                                                                                                                                                                                                                                                                                                                |
| Dr. Paul V. Holland    |   | 74  | Dr. Paul V. Holland, a director of the Company since 2008, has served as the Scientific Director of Delta Blood Bank in Stockton, California since 2004 and as the Medical Director of PacifiCord, a division of Healthbanks Biotech USA Inc., since 2008.  He has been involved in blood banking and transfusion medicine for over 40 years including service as Chief of the Blood Bank Department of the Clinical Center of the National Institutes of Health from 1974 to 1983, Medical Director and CEO of the Sacramento Medical Foundation Blood Center, currently doing business as BloodSource, from 1983 to 2004, a Clinical Professor of Medicine in the Division of Hematology/Oncology at UC Davis Medical Center from 1984 to the present, and as a Clinical Professor of Pathology in the Department of Pathology at UC Davis Medical Center from 2004 to the present.  Dr. Holland has also advised biotech companies, U.S and foreign governments, agencies and non-governmental organizations, including the World Health Organization. He has also served as President of the International Society of Blood Transfusion and as a member of the nominating committee for the Nobel Prize in Medicine and Physiology.  Dr. Holland therefore brings to the Board a significant and broad knowledge of the blood banking and transfusion medicine fields and his scientific and medical expertise are a key part of the Board’s continuing understanding of the Company’s technology and industry.  |

----

| Ronny B. Lancaster      |   | 59 | Ronny B. Lancaster, a director of the Company since 2008, has served as Senior Vice President of Federal Government Relations since 2005 for Assurant, Inc. (NYSE: AIZ), a Fortune 500 company providing specialized insurance products.  He previously served as Senior Vice President and Chief Operating Officer of Morehouse School of Medicine in Atlanta, and Executive Assistant to the Secretary and Principal Deputy Assistant Secretary for Planning and Evaluation of the U.S. Department of Health and Human Services.  Mr. Lancaster earned a B.A. in Economics from the Catholic University of America, an MBA from the Wharton School of the University of Pennsylvania, and a J.D. from Georgetown University Law Center.  He currently sits on the board of directors of OraSure Technologies, Inc. (Nasdaq: OSUR), an oral fluid diagnostic company, and on the Medical Advisory Board of Henry Schein, Inc., a distributor of healthcare products and services.  Mr. Lancaster’s leadership experience in other organizations and his familiarity with the healthcare industry and healthcare policy make him a valuable member of the Board.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dr. Paul D. Mintz  |   | 62 | Paul D. Mintz, M.D., a director of the Company since 2010, served on the faculty at the University of Virginia School of Medicine for more than 31 years principally as a tenured Professor of Pathology and Medicine.  He also served as director of the University of Virginia Health System’s Clinical Laboratories and Transfusion Medicine Services as well as Chief of the Department of Pathology’s Division of Clinical Pathology.  Dr. Mintz was also a co-medical director of Virginia Blood Services for several years.  Dr. Mintz has served throughout his career and continues to serve on numerous national and regional boards and committees for such agencies and organizations as the Centers for Medicare and Medicaid Services, the National Blood Foundation and the AABB (formerly the American Association of Blood Banks). He is a past president of AABB and served for several years on its FDA Advisory Committee, including as past chair.  Currently,  Dr. Mintz is an advisor to the data coordinating center for the National Heart, Lung, and Blood Institute’s multi-site, multi year Recipient Epidemiology and Donor Evaluation Study.  He is also Section Editor of Transfusion Medicine for the AMERICAN JOURNAL OF CLINICAL PATHOLOGY.  Dr. Mintz has published and presented  more than 300 scientific and technical reports relating to blood banking and transfusion medicine.  He is the sole editor of all three editions of a principal text in transfusion medicine.  Dr. Mintz is currently the chair of Immucor’s Scientific Advisory Board, which provides scientific expertise and strategic counsel on a variety of scientific, clinical, and technical issues.  Dr. Mintz’s extensive experience in blood banking and transfusion medicine and familiarity with Immucor make him a valuable addition to Immucor’s Board.  |
| G. Mason Morfit    |   | 35 | G. Mason Morfit, a director of the Company since 2010, is a partner with ValueAct Capital, an investment management firm with $6.54 billion in assets under management. ValueAct Capital is currently Immucor’s largest shareholder. Prior to joining ValueAct Capital in 2001, Mr. Morfit worked in equity research for Credit Suisse First Boston. Mr. Morfit is a director of Valeant Pharmaceuticals International (NYSE: VRX) and a former director of Advanced Medical Optics, Solexa, Inc. and MSD Performance, Inc. He has a B.A. from Princeton University and is a CFA charterholder.  Mr. Morfit’s business experience and his strong alignment with shareholder interests make him an important part of the Board’s leadership and decision-making process.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

----

| Chris E. Perkins  |   | 48 | Chris E. Perkins, a director of the Company since 2008, was until December 2010 an executive with Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX), a healthcare information technology provider of clinical, financial analytics and connectivity solutions to healthcare organizations.  Mr. Perkins worked on the post-merger integration of Allscripts and Eclipsys Corporation, which was completed in August 2010.  At the time of the merger, Mr. Perkins was Executive Vice President and Chief Financial Officer of Eclipsys, a provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services to healthcare organizations.  Previously, from 2001 to 2007, he served as the Chief Financial Officer and then Executive Vice President and Chief Operating Officer of Per-Se Technologies, a systems technology and outsource service provider to the healthcare industry that was acquired by McKesson Corporation.  He also served as Executive Vice President and Chief Operating Officer of Emageon Inc., a healthcare technology company, from December 2007 until he resigned in July 2008.  With nearly 20 years experience in senior financial and operating management positions in several publicly traded companies as well as seven years experience as a CPA in public accounting, Mr. Perkins’ background makes him well-suited to serve on the Board and participate in the oversight of the Company’s financial and risk management processes.  |
|------------------------|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Joseph E. Rosen   |   | 67 | Joseph E. Rosen has been a director of the Company since its founding in 1982, except for a three-year hiatus from 1995 to 1998, and has served as Chairman of the Board of Directors since September 2006. Since 2002, he has served as Director – Business Development and Planning for BioLife Plasma Services, a part of Baxter International. Previously, Mr. Rosen had been employed in various capacities, including CFO, at Sera-Tec Biologicals since its inception in 1969, ultimately serving as its CEO from 1986 until 2001. Mr. Rosen is currently serving on the board of the PPTA Source, the plasma collection industry trade group, and has been a member of the board of directors of several public and private health care companies. He has over 40 years of experience in the blood banking industry and he has been a director of the Company for over 25 years.  This industry background, together with his extensive familiarity with the Company, its products and its development gives Mr. Rosen a unique viewpoint to lead the Board.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

----

----

| Name of Executive Officer |   | Age |   | Position and Biographical information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Since |
|---------------------------|--------|-----|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| Joshua H. Levine          |   | 52  |   | Mr. Levine has served as President and Chief Executive Officer since June 10, 2011.  Please see biography above under “Board of Directors.”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2011  |
| Richard A. Flynt          |   | 52  |   | Mr. Flynt serves as Executive Vice President, Chief Financial Officer and joined the Company in December 2007.  Mr. Flynt is a Certified Public Accountant with more than 25 years of financial management experience.  He has most recently served as Vice President – Finance with McKesson Corporation in Alpharetta, Georgia.  From July 2004 through January 2007, he was Senior Vice President – Corporate Controller & Chief Accounting Officer with Per-Se Technologies, Inc., which was acquired by McKesson Corporation in January 2007.  From 1997 through 2004, he served in a variety of senior financial management positions with GNB Technologies, Inc., Exide Technologies, Inc. and GTS Energy.  Prior to that, he had 15 years of public accounting experience with Ernst & Young LLP. Mr. Flynt earned a BBA and Masters of Accounting from the University of Georgia.  | 2007  |
| Philip H. Moïse      |   | 61  |   | Mr. Moïse serves as Executive Vice President, General Counsel and Secretary and joined the Company in April 2007. Before joining the Company, Mr. Moïse was in the private practice of law, most recently as a partner and Co-Chair of Life Sciences at Sutherland Asbill & Brennan LLP in Atlanta. During a 30-year career in private practice, he represented over 35 public and private companies in the life sciences and medical products industries, and he had represented the Company for more than 20 years. Mr. Moïse graduated with honors from The Citadel and Duke University School of Law.                                                                                                                                                                                                                                                                                                                                      | 2007  |

----

|   | ● | Dr. Gioacchino De Chirico, President and Chief Executive Officer for fiscal 2011 and until his retirement in June 2011; |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------|

|   | ● | Richard A. Flynt, Executive Vice President and Chief Financial Officer; |
|--------|---------|-------------------------------------------------------------------------|

|   | ● | Philip H. Moïse Executive Vice President, General Counsel and Secretary; and |
|--------|---------|-----------------------------------------------------------------------------------|

|   | ● | Geoffrey S. Crouse, Executive Vice President and Chief Operating Officer until his resignation in April 2011. |
|--------|---------|---------------------------------------------------------------------------------------------------------------|

----

| ● | Include performance measures that recognize overall company performance as well as individual performance;                                                                                                                     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ● | Include plans that are competitive externally but flexible enough to deliver rewards based on an executive’s ability to influence our financial and organizational performance and to influence individual performances; |

| ● | Reflect that outstanding company performance should be accompanied by outstanding rewards, and performance below expectations should result in lesser rewards or no rewards; |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ● | Reflect that outstanding individual performance should be accompanied by outstanding rewards within limits of company performance;                                           |

| ● | Provide flexibility and discretion in applying the compensation principles to appropriately reflect individual circumstances as well as changing business conditions and priorities; and |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ● | Include a mix of compensation that balances rewards for achievement of our short- and long-term financial goals and rewards linked to the performance of our stock.                      |

----

| Affymetrix Inc.                         | Myriad Genetics Inc.         |
|-----------------------------------------|------------------------------|
| Align Technology, Inc.                  | Orthofix, International N.V. |
| American Medical Systems Holdings, Inc. | Quidel Corp.                 |
| Gen-Probe Inc.                          | Steris Corp.                 |
| Haemonetics Corp.                       | Teleflex Incorporated        |
| Hill-Rom Holdings, Inc.                 | Thoratec Corp.               |
| ICU Medical Inc.                        | Zoll Medical Corp.           |

|   | ● | Base salary, |
|--------|---------|--------------|

|   | ● | Annual cash incentives (bonuses), and |
|--------|---------|---------------------------------------|

|   | ● | Stock-based long-term incentives. |
|--------|---------|-----------------------------------|

----

| ● | Net Income Component:  actual net income compared to fiscal 2011 target net income; |
|---------|-----------------------------------------------------------------------------------------------|

| ● | Corporate Goals Component:  the achievement of corporate goals established by the Compensation Committee for fiscal 2011; and |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------|

| ● | Individual Goals Component:  the achievement of individual performance objectives for fiscal 2011. |
|---------|--------------------------------------------------------------------------------------------------------------|

----

| Gioacchino De Chirico | President and Chief Executive Officer | $595,000 |
|-----------------------|---------------------------------------|----------|
| Richard A. Flynt      | Executive VP, Chief Financial Officer | $365,000 |
| Philip H. Moïse  | Executive VP, General Counsel         | $503,000 |
| Geoffrey S. Crouse    | Executive VP, Chief Operating Officer | $475,000 |

| ● | Net Income Component:  actual net income compared to fiscal 2011 target net income (“Target Net Income”); |
|---------|---------------------------------------------------------------------------------------------------------------------------------|

| ● | Corporate Goals Component:  the achievement of corporate goals established by the Compensation Committee for fiscal 2011; and |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------|

| ● | Individual Goals Component:  the achievement of individual performance objectives for fiscal 2011. |
|---------|--------------------------------------------------------------------------------------------------------------|

----

| Maximum Bonus Award(% of Base Compensation)* |   | 100% of Target Net Income |   |   | 105% of Target Net Income |   |   | 110% of Target Net Income or Above |   |
|----------------------------------------------|--------|---------------------------|--------|--------|---------------------------|--------|--------|------------------------------------|--------|
| CEO                                          |   | 45%                       |   |   | 67.5%      |   |   | 90%                                |   |
| Other Executive Officers                     |   | 30%                       |   |   | 45%                       |   |   | 60%                                |   |

| * | Maximum bonus awards will be prorated for in-between percentage of net income. |
|---|--------------------------------------------------------------------------------|

| Gioacchino De Chirico | $260,461 |
|-----------------------|----------|
| Richard A. Flynt      | $106,519 |
| Philip H. Moïse  | $146,792 |

| Chief Executive Officer        | 150% of base compensation |
|--------------------------------|---------------------------|
| Other Named Executive Officers | 100% of base compensation |

----

----

|  Name and Principal Position |   | Year   |   | Salary        |   |   | StockAwards(1) |   |   | OptionAwards(1) |   |   | Non-EquityIncentive PlanCompensation (2) |   |   | All OtherCompensation (3) |   |   | Total     |   |
|-----------------------------------|--------|--------|--------|---------------|--------|--------|----------------|--------|--------|-----------------|--------|--------|------------------------------------------|--------|--------|---------------------------|--------|--------|-----------|--------|
|                              |   |   |   | ($)           |   |   | ($)            |   |   | ($)             |   |   | ($)                                      |   |   | ($)                       |   |   | ($)       |   |
| Dr. Gioacchino De Chirico (4)     |   | 2011   |   | 595,776       |   |   | 562,877        |   |   | 302,813         |   |   | 260,461                                  |   |   | 65,629                    |   |   | 1,787,556 |   |
| Past President and                |   | 2010   |   | 571,304       |   |   | 565,841        |   |   | 294,823         |   |   | 50,624                                   |   |   | 66,194                    |   |   | 1,548,786 |   |
| Chief Executive Officer           |   | 2009   |   | 571,828       |   |   | 394,220        |   |   | 730,666         |   |   | 294,687                                  |   |   | 44,419                    |   |   | 2,035,820 |   |
|                              |   |   |   |          |   |   |           |   |   |            |   |   |                                     |   |   |                      |   |   |      |   |
| Richard A. Flynt                  |   | 2011   |   | 363,008       |   |   | 256,016        |   |   | 85,265          |   |   | 106,519                                  |   |   | 33,221                    |   |   | 844,029   |   |
| Executive Vice President          |   | 2010   |   | 339,546       |   |   | 200,298        |   |   | 64,605          |   |   | 34,283                                   |   |   | 21,608                    |   |   | 660,340   |   |
| Chief Financial Officer           |   | 2009   |   | 292,662       |   |   | 121,292        |   |   | 224,815         |   |   | 106,575                                  |   |   | 23,167                    |   |   | 768,511   |   |
|                              |   |   |   |          |   |   |           |   |   |            |   |   |                                     |   |   |                      |   |   |      |   |
| Philip H. Moïse              |   | 2011   |   | 501,134       |   |   | 367,465        |   |   | 122,381         |   |   | 146,792                                  |   |   | 32,913                    |   |   | 1,170,685 |   |
| Executive Vice President          |   | 2010   |   | 488,973       |   |   | 322,238        |   |   | 103,935         |   |   | 49,207                                   |   |   | 21,962                    |   |   | 986,314   |   |
| General Counsel                   |   | 2009   |   | 472,115       |   |   | 194,944        |   |   | 361,321         |   |   | 171,463                                  |   |   | 19,441                    |   |   | 1,219,284 |   |
|                              |   |   |   |          |   |   |           |   |   |            |   |   |                                     |   |   |                      |   |   |      |   |
| Geoffrey S. Crouse (5)            |   | 2011   |   | 476,442       |   |   | 338,853        |   |   | 819,358         |   |   | ―                                  |   |   | 1,116,784                 |   |   | 2,751,437 |   |
| Former Executive Vice President   |   | 2010   |   | 372,034       |   |   | 168,500        |   |   | 334,022         |   |   | 37,812                                   |   |   | 229,868                   |   |   | 1,142,236 |   |
| Chief Operating Officer           |   | 2009   |   |  ― |   |   | ―        |   |   | ―         |   |   | ―                                  |   |   | ―                   |   |   | ―   |   |

| (1)   | The amounts in these columns reflect the aggregate grant date fair value, as computed in accordance with Accounting Standards Codification 718, of awards pursuant to the Company’s equity incentive plans. Assumptions used in the calculation of these amounts for awards granted in fiscal year 2011 are included in Note 12, “Share-Based Compensation”, to the Company’s audited financial statements for the fiscal year ended May 31, 2011, included in the Company’s Annual Report on Form 10-K filed with the SEC on July 20, 2011. These referenced sections are deemed part of the disclosure required under Item 402 of SEC Regulation S-K. All the awards listed above were equity awards and consequently aggregate grant date fair value is fixed. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | We paid bonuses for fiscal 2011 at the beginning of fiscal 2012 based on the achievement of approximately 100% of the fiscal 2011 Target Net Income, and corporate and individual goals established under the Company’s 2011 Bonus Plan at the end of fiscal 2010.  The 2011 Bonus Plan is described in greater detail in the Compensation Discussion and Analysis section of this report. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | All Other Compensation consisted of the following: |
|-----|----------------------------------------------------|

|  Name                |   |   AutoAllowance |   |   | Financial Planning/Legal Fees |   |    | InsurancePremiums |   |   | CompanyContributionsto Retirement and401(k) Plans |   |   |  SeverancePayments/Accruals |   |   | Total  |   |
|---------------------------|--------|----------------------|--------|--------|-------------------------------|--------|---------|-------------------|--------|--------|-------------------------------------------------------------|--------|--------|----------------------------------|--------|--------|--------|--------|
|                      |   | ($)                  |   |   | ($)                           |   |    | ($)               |   |   | ($)                                                         |   |   | ($)                              |   |   | ($)    |   |
| Dr. Gioacchino De Chirico |   |                 | 12,012 |   |                          |   | ― |              |   |   | 43,786                                                      |   |   |                             | 9,831  |   |   |   | ― |   |   |   | 65,629 |   |
| Richard A. Flynt          |   |                 | 12,015 |   |                          |   | ― |              |   |   | 11,022                                                      |   |   |                             | 10,184 |   |   |   | ― |   |   |   | 33,221 |   |
| Philip H. Moïse      |   |                 | 11,922 |   |                          |   | ― |              |   |   | 13,191                                                      |   |   |                             | 7,800  |   |   |   | ― |   |   |   | 32,913 |   |
| Geoffrey S. Crouse        |   |                 | 10,582 |   |                          |   | 6,823   |              |   |   | 5,447                                                       |   |   |                             | 8,723  |   |   |   | 1,085,209 |   |   |   | 1,116,784 |   |

| (4) | In August 2009, the Compensation Committee approved an increase in Dr. De Chirico’s base compensation, but he voluntarily declined the increase.  In addition, Dr. De Chirico was entitled to receive $337,687 under the 2009 Bonus Plan but voluntarily declined $43,000 of that amount, which was the portion related to the additional expenses incurred during fiscal 2009 related to the Company’s Quality Process Improvement Project.  |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5) | Mr. Crouse joined the Company in August 2009.  During fiscal 2011 he served as Executive Vice President, Chief Operating Officer until his resignation in April 2011.                                                                                                                                                                                                                                                                                          |

----

|                                        |   |      |   | Estimated Future PayoutsUnder Non-EquityIncentive Plan Awards (1) |   |      |   |       |   |                                                               |   |                                                                        |   |
|---------------------------------------------|--------|-----------|--------|-------------------------------------------------------------------|--------|-----------|--------|------------|--------|--------------------------------------------------------------------|--------|-----------------------------------------------------------------------------|--------|
| Name                                        |   | GrantDate |   | Threshold($)                                                      |   | Target($) |   | Maximum($) |   | All OtherStock Awards:Number of Shares ofStock orUnits (2)(#) |   | All OtherOption Awards:Number of SecuritiesUnderlyingOptions (2)(3)(#) |   | Exercise orBase Priceof OptionAwards($ / Sh) |   | Grant Date FairValue of Stock and Option Awards ($) |   |
| Dr. Gioacchino De Chirico                   |   |      |   |                                                              |   |      |   |       |   |                                                               |   |                                                                        |   |   |   |   |   |
| Past President and                          |   | 6/7/10    |   |                                                              |   |      |   |       |   |                                                               |   | 42,106                                                                      |   | 19.10 |   | 302,813 |   |
| Former Chief Executive Officer              |   | 6/7/10    |   |                                                              |   |      |   |       |   | 29,470                                                             |   |                                                                        |   |   |   | 562,877 |   |
|                                        |   |      |   | ―                                                           |   | 267,750   |   | 535,500    |   |                                                               |   |                                                                        |   |   |   |   |   |
| Richard A. Flynt                            |   |      |   |                                                              |   |      |   |       |   |                                                               |   |                                                                        |   |   |   |   |   |
| Executive Vice President                    |   | 6/7/10    |   |                                                              |   |      |   |       |   |                                                               |   | 11,856                                                                      |   | 19.10 |   | 85,265 |   |
| Chief Financial Officer                     |   | 6/7/10    |   |                                                              |   |      |   |       |   | 13,404                                                             |   |                                                                        |   |   |   | 256,016 |   |
|                                        |   |      |   | ―                                                           |   | 109,500   |   | 219,000    |   |                                                               |   |                                                                        |   |   |   |   |   |
| Philip H. Moïse                        |   |      |   |                                                              |   |      |   |       |   |                                                               |   |                                                                        |   |   |   |   |   |
|   Executive Vice President        |   | 6/7/10    |   |                                                              |   |      |   |       |   |                                                               |   | 17,017                                                                      |   | 19.10 |   | 122,381 |   |
| General Counsel                             |   | 6/7/10    |   |                                                              |   |      |   |       |   | 19,239                                                             |   |                                                                        |   |   |   | 367,465 |   |
|                                        |   |      |   | ―                                                           |   | 150,900   |   | 301,800    |   |                                                               |   |                                                                        |   |   |   |   |   |
| Geoffrey S. Crouse                          |   |      |   |                                                              |   |      |   |       |   |                                                               |   |                                                                        |   |   |   |   |   |
|   Former Executive Vice President |   | 6/7/10    |   |                                                              |   |      |   |       |   |                                                               |   | 15,691                                                                      |   | 19.10 |   | 112,845 |   |
| Chief Operating Officer                     |   | 7/16/10   |   |                                                              |   |      |   |       |   |                                                               |   | 100,000                                                                     |   | 18.53 |   | 706,513 |   |
|                                        |   | 6/7/10    |   |                                                              |   |      |   |       |   | 17,741                                                             |   |                                                                        |   |   |   | 338,853 |   |
|                                        |   |      |   | ―                                                           |   | 142,500   |   | 285,000    |   |                                                               |   |                                                                        |   |   |   |   |   |

----

| (1)   | Actual payouts in August 2011 to the Named Executive Officers under the 2011 Bonus Plan are reported under the Non-Equity Incentive Plan Compensation column in the Summary Compensation Table. The Compensation Discussion and Analysis section of this report explains in greater detail the methodology used for calculating bonuses. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | On June 7, 2010 as part of the annual group award under the 2011 Stock Incentive Plan, the Compensation Committee granted options to purchase shares of common stock and restricted share awards to employees of the Company, including Named Executive Officers, pursuant to the 2005 Long-Term Incentive Plan. The options vest 25% at each anniversary of the grant date and have a term of six years, and restricted shares vest 20% at each anniversary of the grant date. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)  | On July 16, 2010, Mr. Crouse was granted stock options upon his promotion to Executive Vice President and Chief Operating Officer. |
|-----------|------------------------------------------------------------------------------------------------------------------------------------|

|                      |   | Option Awards (1)                                  |    | Stock Awards (2) |                                               |
|---------------------------|--------|----------------------------------------------------|---------|-----------------------|----------------------------------------------------|
|                      |   | Number ofSecuritiesUnderlyingUnexercisedOptions(#) |    |                  | Number ofSecuritiesUnderlyingUnexercisedOptions(#) |   |   |   OptionExercise Price |   | Option |   | Number ofShares orUnits ofStock ThatHave Not Vested |   |   | MarketValue ofShares orUnits ofStock ThatHave Not Vested |   |
| Name                      |   | Exercisable                                        |    |                  | Unexercisable                                      |   |   | ($) |   | Expiration |   | (#) |   |   | ($) |   |
| Dr. Gioacchino De Chirico |   |                                               | 28,368  |                  |                                               |   | ― |   |   |   | 17.51 |   | 6/6/2012 |   |   |   |   |   |   |
|                      |   |                                               | 42,249  |                  |                                               |   | 14,084 |   |   |   | 29.23 |   | 6/8/2013 |   |   |   |   |   |   |
|                      |   |                                               | 35,193  |                  |                                               |   | 35,194 |   |   |   | 26.90 |   | 6/5/2014 |   |   |   |   |   |   |
|                      |   |                                               | 11,810  |                  |                                               |   | 35,431 |   |   |   | 16.25 |   | 6/4/2015 |   |   |   |   |   |   |
|                      |   |                                               | ― |                  |                                               |   | 42,106 |   |   |   | 19.10 |   | 6/7/2016 |   |   |   |   |   |   |
|                      |   |                                               |    |                  |                                               |   |   |   |   |   |   |   |   |   |   | 72,866 |   |   |   | 1,525,085 |   |
| Richard A. Flynt          |   |                                               | 11,250  |                  |                                               |   | 3,750 |   |   |   | 33.24 |   | 12/10/2013 |   |   |   |   |   |   |   |   |
|                      |   |                                               | 10,828  |                  |                                               |   | 10,829 |   |   |   | 26.90 |   | 6/5/2014 |   |   |   |   |   |   |   |   |
|                      |   |                                               | 2,588   |                  |                                               |   | 7,764 |   |   |   | 16.25 |   | 6/4/2015 |   |   |   |   |   |   |   |   |
|                      |   |                                               | ― |                  |                                               |   | 11,856 |   |   |   | 19.10 |   | 6/7/2016 |   |   |   |   |   |   |   |   |
|                      |   |                                               |    |                  |                                               |   |   |   |   |   |   |   |   |   |   | 25,971 |   |   |   | 543,573 |   |
| Philip H. Moïse      |   |                                               | 15,000  |                  |                                               |   | ― |   |   |   | 30.00 |   | 4/1/2013 |   |   |   |   |   |   |   |   |
|                      |   |                                               | 21,937  |                  |                                               |   | 7,313 |   |   |   | 29.23 |   | 6/8/2013 |   |   |   |   |   |   |   |   |
|                      |   |                                               | 17,403  |                  |                                               |   | 17,404 |   |   |   | 26.90 |   | 6/5/2014 |   |   |   |   |   |   |   |   |
|                      |   |                                               | 4,163   |                  |                                               |   | 12,491 |   |   |   | 16.25 |   | 6/4/2015 |   |   |   |   |   |   |   |   |
|                      |   |                                               | ― |                  |                                               |   | 17,017 |   |   |   | 19.10 |   | 6/7/2016 |   |   |   |   |   |   |   |   |
|                      |   |                                               |    |                  |                                               |   |   |   |   |   |   |   |   |   |   | 41,972 |   |   |   | 878,474 |   |
| Geoffrey S. Crouse (3)    |   |                                               | 50,000  |                  |                                               |   | ― |   |   |   | 16.85 |   | 8/3/2015 |   |   |   |   |   |   |   |   |
|                      |   |                                               | 15,691  |                  |                                               |   | ― |   |   |   | 19.10 |   | 6/7/2016 |   |   |   |   |   |   |   |   |
|                      |   |                                               | 100,000 |                  |                                               |   | ― |   |   |   | 18.53 |   | 7/16/2016 |   |   |   |   |   |   |   |   |

| (1)  | All option awards are non-qualified stock options. Options granted prior to June 1, 2006 expire ten years from the date of grant. Options issued on or after June 1, 2006 expire six years from the date of grant. The vesting schedule for the options granted prior to June 1, 2006 is 50% on the second anniversary of the grant date and 25% on each of the third and fourth anniversaries of the grant date; the vesting schedule for the options granted on or after June 1, 2006 is 25% on each anniversary of the grant date. Restricted shares vest 20% at each anniversary of the date of grant. |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | The market value of outstanding stock awards is based on a per share value of $20.93, the closing market price of our stock on May 31, 2011.                                     |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|            |                                                                                                                                                                                  |
| (3)   | Pursuant to the terms of Mr. Crouse’s employment agreement, all unvested stock options became exercisable on his resignation, and remain exercisable for their remaining terms. |

----

| Fiscal 2011 Option Exercises And Stock Vested Table |   |
|-----------------------------------------------------|--------|
|                                                |   |   |   |   |   |   |
|                                                |   | Option Awards |   |   | Stock Awards |   |
| Name                                                |   | Number of SharesAcquired onExercise(#) |   |   | Value Realizedon Exercise (1)($) |   |   | Number of SharesAcquired onVesting(#) |   |   | Value Realizedon Vesting (2)($) |   |
| Dr. Gioacchino De Chirico                           |   |   | - |   |   |   | - |   |   |   | 14,214 |   |   |   | 273,061 |   |
|                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Richard A. Flynt                                    |   |   | - |   |   |   | - |   |   |   | 3,367 |   |   |   | 65,050 |   |
|                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Philip H. Moïse                                |   |   | - |   |   |   | - |   |   |   | 6,675 |   |   |   | 128,155 |   |
|                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Geoffrey S. Crouse (3)                         |   |   | - |   |   |   | - |   |   |   | 27,741 |   |   |   | 581,163 |   |

| (1)   | The value realized equals the difference between the closing market price of our common stock on the date of exercise and the exercise price multiplied by the number of shares acquired on exercise. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | The value realized equals the closing market price of our common stock on the vesting date multiplied by the number of shares acquired on vesting.                              |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|            |                                                                                                                                                                            |
| (3)   | Pursuant to the terms of Mr. Crouse’s employment agreement, all restricted shares vested and all restrictions imposed on the restricted shares lapsed on his resignation. |

----

----

|   | ● | Sale of the Company’s Assets.  The sale of all or substantially all of the Company’s assets to a single purchaser or group of associated purchasers, whether in a single transaction or a series of related transactions within a 12-month period. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | Sale of the Company’s Shares.  The sale, exchange, or other disposition to a single purchaser or group of associated purchasers, in one transaction, or in a series of related transactions within a 12-month period, of 30% or more of the Company’s outstanding shares of capital stock. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | Merger or Consolidation.  The merger or consolidation of the Company in a transaction or series of related transactions in which the Company’s shareholders receive or retain less than 50% of the outstanding voting shares of the new or surviving corporation. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | Employee’s material dishonesty in connection with his employment with the Company that causes harm to the Company; |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------|

|   | ● | Employee’s continuing refusal to perform reasonable duties assigned to him that are consistent with employee’s position (subject to certain notice and cure periods); or |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | Employee’s breach of any of the material terms of the agreement (subject to certain notice and cure periods). |
|--------|---------|---------------------------------------------------------------------------------------------------------------------|

|   | ● | the assignment to employee of any duties or responsibilities materially inconsistent with the scope of the duties or responsibilities associated with his title or position, or any material adverse change of his title, position or status or the circumstances of his employment; |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | any action or inaction by the Company which would materially and adversely affect employee’s base compensation or participation in, or materially reduce his benefits under, the Company’s benefit plans (including, without limitation, equity benefits) as of the effective date of the agreement or as may be increased thereafter, other than actions or inactions that apply to all executive officers of the Company generally; |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | a breach by the Company of any of the material terms of the agreement; |
|--------|---------|------------------------------------------------------------------------|

|   | ● | the Company’s relocation of its headquarters to, or requiring the employee to move his primary work location to, a place more than 30 miles from the Company’s current headquarters location in Norcross, Georgia. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ● | The termination and/or the qualified change in control event occurred on May 31, 2011 (the last business day of our last completed fiscal year); |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------|

| ● | The price per share of our common stock on the date of termination is $20.93, the closing market price of our common stock on the Nasdaq Global Select Market on May 31, 2011. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                 |   |                 |   | Before Change inControl |    |   | After Change inControl |   |      |                    |   |
|--------------------------------------|--------|----------------------|--------|-----------------------------------|---------|--------|----------------------------------|--------|-----------|-------------------------|--------|
| Name                                 |   | Benefit              |   | Terminationw/o Cause ($)     |    |   | Terminationw/o Cause ($)    |   |      | Death or Disability ($) |   |
| Dr. Gioacchino De Chirico            |   | Severance            |   |                              | 753,377 |   |                             |   | 1,502,637 |                    |   |   | - |   |
|   Past President and       |   | Stock Options (1)    |   |                              | -       |   |                             |   | 2,654,238 |                    |   |   | 2,654,238 |   |
|   Chief Executive Officer  |   | Restricted Stock (2) |   |                              | -       |   |                             |   | 1,525,085 |                    |   |   | 1,525,085 |   |
|                                 |   | Outplacement         |   |                              | -       |   |                             |   | 30,000    |                    |   |   | -  |   |
|                                 |   |                 |   |                              |    |   |                             |   |      |                    |   |   |   |   |
|                                 |   | TOTAL (3)            |   |                              | 753,377 |   |                             |   | 5,711,960 |                    |   |   | 4,179,323 |   |
|                                 |   |                 |   |                              |    |   |                             |   |      |                    |   |   |   |   |
| Richard A. Flynt                     |   | Severance            |   |                              | 229,172 |   |                             |   | 866,818   |                    |   |   | - |   |
|   Executive Vice President |   | Stock Options (1)    |   |                              | -       |   |                             |   | 715,785   |                    |   |   | 715,785 |   |
|   Chief Financial Officer  |   | Restricted Stock (2) |   |                              | -       |   |                             |   | 543,573   |                    |   |   | 543,573 |   |
|                                 |   | Outplacement         |   |                              | -       |   |                             |   | 30,000    |                    |   |   | - |   |
|                                 |   |                 |   |                              |    |   |                             |   |      |                    |   |   |   |   |
|                                 |   | TOTAL (3)            |   |                              | 229,172 |   |                             |   | 2,156,176 |                    |   |   | 1,259,358 |   |
|                                 |   |                 |   |                              |    |   |                             |   |      |                    |   |   |   |   |
| Philip H. Moïse                 |   | Severance            |   |                              | -       |   |                             |   | 1,198,267 |                    |   |   | - |   |
|   Executive Vice President |   | Stock Options (1)    |   |                              | -       |   |                             |   | 1,134,929 |                    |   |   | 1,134,929 |   |
|   General Counsel          |   | Restricted Stock (2) |   |                              | -       |   |                             |   | 878,474   |                    |   |   | 878,474 |   |
|                                 |   | Outplacement         |   |                              | -       |   |                             |   | 30,000    |                    |   |   | - |   |
|                                 |   |                 |   |                              |    |   |                             |   |      |                    |   |   |   |   |
|                                 |   | TOTAL (3)            |   |                              | -       |   |                             |   | 3,241,670 |                    |   |   | 2,013,403 |   |

| (1)   | This value equals the difference between the closing market price of our common stock on May 31, 2011 and the exercise price, multiplied by the number of option shares subject to accelerated vesting. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | This value is calculated based on the closing market price of our common stock on May 31, 2011. |
|-----------------|------------------------------------------------------------------------------------------------------|

| (3)   | The total excludes the annual cash incentive for fiscal 2011 paid in August 2011, which is already included as compensation earned in fiscal 2011 in the Summary Compensation Table. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Name                    |   | Fees Earned orPaid in Cash (1) ($) |    |   | Stock Awards(2) (4) ($) |   |    | Option Awards(2) (3) (4) ($) |   |   | Total($) |   |
|-------------------------|--------|-------------------------------------------------------------|---------|--------|------------------------------|--------|---------|-----------------------------------|--------|--------|----------|--------|
| Joseph  Rosen |   |                                                        | 100,000 |   |                         |   | 54,626  |                              |   |   | 29,507   |   |   |   | 184,133 |   |
| James Clouser           |   |                                                        | 65,000  |   |                         |   | 54,626  |                              |   |   | 29,507   |   |   |   | 149,133 |   |
| Paul Holland            |   |                                                        | 55,000  |   |                         |   | 54,626  |                              |   |   | 29,507   |   |   |   | 139,133 |   |
| Ronny Lancaster         |   |                                                        | 60,000  |   |                         |   | 54,626  |                              |   |   | 29,507   |   |   |   | 144,133 |   |
| Paul Mintz              |   |                                                        | 58,167  |   |                         |   | 54,626  |                              |   |   | 29,507   |   |   |   | 142,300 |   |
| G. Mason Morfit (5)     |   |                                                        | 45,167  |   |                         |   | ― |                              |   |   | 132,404  |   |   |   | 177,571 |   |
| Chris Perkins           |   |                                                        | 65,000  |   |                         |   | 54,626  |                              |   |   | 29,507   |   |   |   | 149,133 |   |

| (1) | Non-employee directors receive an annual retainer of $25,000, $2,500 per meeting, and are reimbursed for all travel expenses to and from meetings of the Board. The Chairman of the Board is paid an additional $40,000 annual retainer, the Audit Committee Chair is paid an additional $15,000 annual retainer and the other Audit Committee members are each paid an additional $10,000 annual retainer, the Compensation Committee Chair and the Governance Committee Chair are each paid an additional $10,000 annual retainer, and the other members of these two Committees are each paid an additional $5,000 annual retainer. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | On June 7, 2010, as part of the annual group award, the Compensation Committee granted restricted shares and options to purchase shares of common stock to non-employee directors pursuant to the 2005 Long-Term Incentive Plan. Restricted shares and options granted to non-employee directors fully vest on the first anniversary of the date of grant. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | The Company provides each of the non-employee directors a grant of an option to purchase shares of the Company’s common stock upon their election or appointment as a director at the stock’s closing market price on the date of grant. On July 23, 2010, upon his appointment to the Board of Directors, stock options to purchase 21,200 shares at a price of $19.30 per share were granted to Mr. Morfit under the Company’s 2005 Long-Term Incentive Plan.  Each director may also receive other grants under the 2005 Long-Term Incentive Plan. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4)    | The amounts in these columns reflect the aggregate grant date fair value, as computed in accordance with Accounting Standards Codification 718, of awards pursuant to the Company’s equity incentive plans. Assumptions used in the calculation of these amounts for awards granted in fiscal year 2011 are included in Note 12, “Share-Based Compensation”, to the Company’s audited financial statements for the fiscal year ended May 31, 2011, included in the Company’s Annual Report on Form 10-K with the SEC on July 20, 2011. These referenced sections are deemed part of the disclosure required under Item 402 of SEC Regulation S-K. All the awards listed above were equity awards and consequently aggregate grant date fair value is fixed. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| (5)    | Mr. Morfit joined the Board in July 2010.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

----

| Name of Beneficial Owner(and address for those owning more than 5%) |   |  Amount and Nature of Beneficial Ownership (1) |   | Percent of Class (%) |
|---------------------------------------------------------------------|--------|-----------------------------------------------------|--------|----------------------|
| James F. Clouser                                                    |   | 24,857                                              | (2)    |                 | * |
| Geoffrey S. Crouse                                                  |   | 184,430                                             | (3)    |                 | * |
| Dr. Gioacchino De Chirico                                           |   | 602,675                                             | (4)    |                 | * |
| Richard A Flynt                                                     |   | 113,120                                             | (5)    |                 | * |
| Dr. Paul V. Holland                                                 |   | 24,857                                              | (6)    |                 | * |
| Ronny B. Lancaster                                                  |   | 32,260                                              | (7)    |                 | * |
| Joshua H. Levine                                                    |   | 65,258                                              | (8)    |                 | * |
| Dr. Paul D. Mintz                                                   |   | 17,380                                              | (9)    |                 | * |
| Philip H. Moïse                                                |   | 164,057                                             | (10)   |                 | * |
| G. Mason Morfit (ValueAct Capital)                                  |   | 8,913,336                                           | (11)   |                 | 12.7 |
| Chris E. Perkins                                                    |   | 24,857                                              | (12)   |                 | * |
| Joseph E. Rosen                                                     |   | 129,337                                             | (13)   |                 | * |
| All directors and executive officers as a group (12 persons)        |   | 10,296,424                                          |   |                 | 14.5 |
|                                                                |   |                                                |   |                 |   |
| BlackRock, Inc.                                                     |   | 5,141,267                                           | (14)   |                 | 7.3 |
| Neuberger Berman Group, LLC                                         |   | 3,706,217                                           | (15)   |                 | 5.3 |
| ValueAct Capital                                                    |   | 8,913,336                                           | (16)   |                 | 12.7 |
| Janus Capital Management LLC                                        |   | 6,338,592                                           | (17)   |                 | 9.0 |

----

| *   | Represents less than 1% of our outstanding common stock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Unless otherwise indicated, the address of each of our directors and executive officers is c/o Immucor, Inc., 3130 Gateway Drive, Norcross, Georgia, 30071.  A person is considered to beneficially own any shares: (a) over which the person exercises sole or shared voting or investment power, or (b) of which the person has the right to acquire beneficial ownership at any time within 60 days (such as through the exercise of stock options). Unless otherwise indicated, voting and investment power relating to the above shares is exercised solely by the beneficial owner or shared by the owner and the owner’s spouse or children. Amounts include restricted shares, both vested and unvested, which have voting rights. On July 2, 2011, the Company entered into a definitive agreement to be acquired by investment funds managed by TPG Capital. If consummated, the transaction will result in a change in control of the Company. Under the terms of the agreement, the Company’s shareholders will receive $27.00 in cash for each share of common stock they own.  In addition, in connection with the transaction, all unvested equity awards held by the executive officers and directors of the Company will be free of all restrictions and will vest.  The transaction is expected to close in the second half of calendar 2011.  |
| (2) | For Mr. Clouser, includes options to purchase 6,644 shares at $30.98, options to purchase 3,286 shares at $16.25, options to purchase 4,103 shares at $19.10 and 5,542 shares of restricted stock that vest one year from the date of grant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (3) | For Mr. Crouse, includes options to purchase 50,000 shares at $16.85, options to purchase 15,691 shares at $19.10 and options to purchase 100,000 shares at $18.53.  Mr. Crouse served as Executive Vice President, Chief Operating Officer from August 2009 until his resignation in March 2011. The information presented in this table with respect to Mr. Crouse is as of April 30, 2011, the most recent practicable date as of which information regarding Mr. Crouse’s ownership was available to the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

----

| (4)  | For Dr. De Chirico, includes options to purchase 28,368 shares at $17.51, options to purchase 56,333 shares at $29.23, options to purchase 52,790 shares at $26.90, options to purchase 23,620 shares at $16.25, options to purchase 10,526 shares at $19.10 and 52,758 restricted stock that vest periodically over the next four years.  Also includes 33,722 restricted stock units and 11,241 performance shares that vest periodically over the next three years. Dr. De Chirico served as President and Chief Executive Officer until his retirement in June 2011.  |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5)  | For Mr. Flynt, includes options to purchase 15,000 shares at $33.24, options to purchase 16,242 shares at $26.90, options to purchase 5,176 shares at $16.25, options to purchase 2,964 shares at $19.10 and 19,924 shares of restricted stock that vest periodically over the next four years.  Also includes 23,000 restricted stock units and 23,904 performance shares that vest periodically over the next three years.                                                                                                                                              |
| (6)  | For Dr. Holland, includes options to purchase 6,644 shares at $30.98, options to purchase 3,286 shares at $16.25, options to purchase 4,103 shares at $19.10 and 5,542 shares of restricted stock that vest one year from the date of grant.                                                                                                                                                                                                                                                                                                                                        |
| (7)  | For Mr. Lancaster, includes options to purchase 9,375 shares at $29.55, options to purchase 3,867 shares at $26.90, options to purchase 3,286 shares at $16.25, options to purchase 4,103 shares at $19.10 and 5,542 shares of restricted stock that vest one year from the date of grant.                                                                                                                                                                                                                                                                                          |
| (8)  | For Mr. Levine, represents 65,258 performance shares which vest over the next three years.  In June 2011, Mr. Levine was appointed President, Chief Executive Officer, and a director of the Company.                                                                                                                                                                                                                                                                                                                                                                     |
| (9)  | For Dr. Mintz, includes options to purchase 4,875 shares at $20.30, options to purchase 4,103 shares at $19.10 and 5,542 shares of restricted stock that vest one year from the date of grant.                                                                                                                                                                                                                                                                                                                                                                                      |
| (10) | For Mr. Moïse, includes options to purchase 15,000 shares at $30.00, options to purchase 29,250 shares at $29.23, options to purchase 26,105 shares at $26.90, options to purchase 8,327 shares at $16.25, options to purchase 4,254 shares at $19.10 and 31,449 shares of restricted stock that vest periodically over the next four years.  Also includes 10,000 restricted stock units and 25,340 performance shares that vest periodically over the next three years.                                                                                            |
| (11) | Represents shares beneficially owned by ValueAct Capital.  Mr. Morfit is attributed beneficial ownership of these shares as a partner of ValueAct Capital, but he disclaims beneficial ownership except to the extent of his pecuniary interest in each ValueAct Capital entity (see note 16 below).                                                                                                                                                                                                                                                                      |
| (12) | For Mr. Perkins, includes options to purchase 6,644 shares at $30.98, options to purchase 3,286 shares at $16.25, options to purchase 4,103 shares at $19.10 and 5,542 shares of restricted stock that vest one year from the date of grant.                                                                                                                                                                                                                                                                                                                                        |
| (13) | For Mr. Rosen, includes options to purchase 63,437 shares at $0.89, options to purchase 25,312 shares at $6.12, options to purchase 2,535 shares at $17.51, options to purchase 3,250 shares at $29.23, options to purchase 3,867 shares at $26.90, options to purchase 3,286 shares at $16.25, options to purchase 4,103 shares at $19.10.  Also includes 140 shares of restricted stock and 5,542 restricted stock units that vest periodically over the next year.                                                                                                     |
| (14) | Based on information contained in a Schedule 13G/A that BlackRock, Inc., 40 East 52nd Street, New York, NY, 10022 filed with the SEC on February 4, 2011. The filing indicated that BlackRock, Inc., had sole voting power and sole dispositive power for 5,141,267 shares.                                                                                                                                                                                                                                                                                                         |
| (15) | Based on information contained in a Schedule 13G/A that Neuberger Berman Group, LLC, 605 Third Avenue, New York, NY, 10158, filed with the SEC on February 14, 2011. The filing indicated that Neuberger Group, LLC, including its affiliate Neuberger Berman, LLC, had shared voting power for 3,226,791 shares and shared dispositive power for 3,706,217 shares.                                                                                                                                                                                                                 |

----

| (16) | Based on information contained in a Schedule 13D/A that ValueAct Capital, 435 Pacific Avenue, 4th floor, San Francisco, CA, 94133, filed with the SEC on July 5, 2011. The filing indicated that ValueAct Capital Master Fund, L.P., including its affiliates VA Partners I, LLC, ValueAct Capital Management, L.P., ValueAct Capital Management, LLC, ValueAct Holdings, L.P. and ValueAct Holdings GP, LLC, had shared voting power and shared dispositive power of 7,540,665 shares and ValueAct SmallCap Master Fund, L.P., including its affiliates VA SmallCap Partners, LLC, ValueAct SmallCap Management, L.P., ValueAct SmallCap Management, LLC, and David Lockwood, had shared voting power and shared dispositive power for 1,372,671 shares.  |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (17) | Based on information contained in a Schedule 13G that Janus Capital Management LLC, 151 Detroit Street, Denver, Colorado, 80206, filed with the SEC on February 14, 2011. The filing indicated that Janus Capital, including its affiliates INTECH Investment Management and Perkins Investment Management LLC, had shared voting power and shared dispositive power for 6,338,592 shares.                                                                                                                                                                                                                                                                                                                                                                      |

----

| Fee Category:      |   | 2011   |      |   | 2010   |   |
|--------------------|--------|--------|-----------|--------|--------|--------|
| Audit fees         |   | $      | 1,524,294 |   |   | $      | 1,535,669 |   |
| Audit-related fees |   |   | 60,973    |   |   |   | 20,000 |   |
| Tax fees           |   |   | ―   |   |   |   | ― |   |
| All other fees     |   |   | ―   |   |   |   | ― |   |
| Total fees         |   | $      | 1,585,267 |   |   | $      | 1,555,669 |   |

----

|   | ● | In the opinion of senior management, the independent registered public accounting firm possesses unique knowledge or technical expertise that is superior to that of other potential providers; |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ● | The approval of the Chair of the Audit Committee is obtained prior to the retention; and |
|--------|---------|------------------------------------------------------------------------------------------|

|   | ● | The retention will not affect the status of the independent registered public accounting firm as “independent accountants” under applicable rules of the SEC, PCAOB and Nasdaq Stock Market. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit |   |                                         |
|---------|--------|----------------------------------------------|
| Number  |   | Description                                  |
|    |   |                                         |
| 31.1    |   | Certification of Principal Executive Officer |
| 31.2    |   | Certification of Principal Financial Officer |

----

| Date:  August 16, 2011 | By:    | /s/ Philip H. Moïse                |   |
|----------------------------------|--------|----------------------------------------------|--------|
|                             |   | Philip H. Moïse                         |   |
|                             |   | Executive Vice President and General Counsel |   |

----

| Exhibit |   |                                         |
|---------|--------|----------------------------------------------|
| Number  |   | Description                                  |
|    |   |                                         |
| 31.1    |   | Certification of Principal Executive Officer |
| 31.2    |   | Certification of Principal Financial Officer |